Summary
7.12 0.16(2.30%)07/03/2024
Mind Medicine Inc (MNMD)
Mind Medicine Inc (MNMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.08 | -2.67 | -17.59 | -39.15 | 99.16 | 96.14 | 0.00 | -26.82 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.12 | |
| Open | 7.00 | |
| High | 7.32 | |
| Low | 7.00 | |
| Volume | 439,031 | |
| Change | 0.15 | |
| Change % | 2.08 | |
| Avg Volume (20 Days) | 1,502,245 | |
| Volume/Avg Volume (20 Days) Ratio | 0.29 | |
| 52 Week Range | 2.41 - 12.22 | |
| Price vs 52 Week High | -41.73% | |
| Price vs 52 Week Low | 195.44% | |
| Range | 1.71 | |
| Gap Up/Down | -0.14 | |
Fundamentals | ||
| Market Capitalization (Mln) | 491 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.00 | |
| Book Value | 0.3940 | |
| Earnings Per Share | -0.1840 | |
| EPS Estimate Current Quarter | -0.0300 | |
| EPS Estimate Next Quarter | -0.0400 | |
| EPS Estimate Current Year | -0.2900 | |
| EPS Estimate Next Year | -0.2900 | |
| Diluted EPS (TTM) | -0.1840 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.5495 | |
| Return on equity (TTM) | -0.9500 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 420,740,992 | |
| Shares Float | 364,340,069 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 15.76 | |
| Institutions (%) | 10.89 | |
06/21 07:00 EST - businesswire.com
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.
06/20 07:00 EST - businesswire.com
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.
06/18 12:31 EST - investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.
06/14 10:40 EST - zacks.com
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
05/29 10:46 EST - zacks.com
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
05/28 07:00 EST - businesswire.com
MindMed to Participate in June Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date and Time: Tuesday, June 4, 2024 at 4:15.
MindMed to Participate in June Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date and Time: Tuesday, June 4, 2024 at 4:15.
05/23 15:41 EST - investorplace.com
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
The Time Traveler's Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.
05/23 12:15 EST - seekingalpha.com
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
Psychedelics Closer To Commercialization; Compass Far And Away The Leader
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
05/10 11:00 EST - investorplace.com
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubtedly a good strategy, there are plenty of top Russell 2000 stocks to buy.
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubtedly a good strategy, there are plenty of top Russell 2000 stocks to buy.
05/09 06:49 EST - investorplace.com
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
05/04 08:00 EST - businesswire.com
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate) in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. The study was presen.
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data from MMED008, its Phase 2b study of MM120 (lysergide d-tartrate) in the treatment of GAD in adults. MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints. The study was presen.
04/25 15:00 EST - investorplace.com
The Top 3 Small-Cap Stocks to Buy in April 2024
Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tides seem to be turning as investors increasingly seek diversification away from a handful of high-multiple tech stocks and toward a more diverse array of product types, operational structures and size — all of which small-cap stocks have in spades.
The Top 3 Small-Cap Stocks to Buy in April 2024
Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tides seem to be turning as investors increasingly seek diversification away from a handful of high-multiple tech stocks and toward a more diverse array of product types, operational structures and size — all of which small-cap stocks have in spades.
04/25 07:00 EST - businesswire.com
MindMed to Present at Upcoming May Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences: American Psychiatric Association (.
MindMed to Present at Upcoming May Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences: American Psychiatric Association (.
04/25 05:37 EST - fool.com
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
Mind Medicine has an exciting treatment option for generalized anxiety disorder -- MM120. In clinical trials, MM120 reduced anxiety in patients after just a single dose.
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
Mind Medicine has an exciting treatment option for generalized anxiety disorder -- MM120. In clinical trials, MM120 reduced anxiety in patients after just a single dose.
04/08 08:01 EST - zacks.com
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
04/04 12:43 EST - seekingalpha.com
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033.
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033.
04/02 07:00 EST - businesswire.com
MindMed to Present at Upcoming April Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences: European Psychiatric Association (EPA) 2024 Congress Title: Prevalence of Generalized Anx.
MindMed to Present at Upcoming April Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences: European Psychiatric Association (EPA) 2024 Congress Title: Prevalence of Generalized Anx.
04/01 17:00 EST - businesswire.com
MindMed Announces Voluntary Delisting from Cboe Canada
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed's common shares will continue to be lis.
MindMed Announces Voluntary Delisting from Cboe Canada
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed's common shares will continue to be lis.
03/11 07:00 EST - businesswire.com
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024. About MindMed MindMed is a clinical stage biopharma.
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024. About MindMed MindMed is a clinical stage biopharma.
03/08 14:46 EST - youtube.com
PLTR, MNMD, ODD: Finding Value in the Market
Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and Arm Holdings (ARM).
PLTR, MNMD, ODD: Finding Value in the Market
Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and Arm Holdings (ARM).